Helicobacter pylori Eradication in Parkinson's Disease: A Randomized Placebo‐Controlled Trial
The DOI matches its Crossref record; 9 of the 9 references it cites were found in a registry or an index.
Abstract
Background: Helicobacter pylori (HP) infection has been associated with worse motor function in Parkinson's disease (PD). Objective: We aimed to evaluate the effects of HP eradication on PD symptoms. Methods: In this parallel‐group, double‐blind, randomized placebo‐controlled, single‐center trial, patients with PD with positive HP urea breath test and serology were block randomized (1:1) to receive standard eradication triple therapy or identically appearing placebo capsules for 1 week. Prespecified motor (International Parkinson and Movement Disorder Society Unified PD Rating Scale [MDS‐UPDRS], timed tests, and home‐based wearable sensor measurements), nonmotor (Leeds Dyspepsia Questionnaire and Montreal Cognitive Assessment), and quality‐of‐life (Parkinson's Disease Questionnaire‐39) outcome measures were assessed at weeks 6, 12, 24, and 52. The primary outcome was the baseline‐to‐week 12 change in ON medication MDS‐UPDRS motor scores. Lactulose‐hydrogen breath testing for concomitant small intestinal bacterial overgrowth was performed at baseline and repeated at week 24, together with the urea breath test. Results: A total of 310 patients were screened for eligibility and 80 were randomly assigned, of whom 67 were included in the full‐analysis set (32 treatment group patients, 35 placebo patients). HP eradication did not improve MDS‐UPDRS motor scores at week 12 (mean difference 2.6 points in favor of placebo, 95% confidence interval: −0.4 to 5.6, P = 0.089). There was no significant improvement in any motor, nonmotor, or quality‐of‐life outcome at weeks 12 and 52. Both the full‐analysis and per‐protocol analyses (based on eradication status) supported these conclusions. Small intestinal bacterial overgrowth status did not influence treatment results. Conclusions: HP eradication does not improve clinical outcomes in PD, suggesting that there is no justification for routine HP screening or eradication with the goal of improving PD symptoms. © 2020 International Parkinson and Movement Disorder Society
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Gastrointestinal Dysfunction in Parkinson’s Disease
Fasano, A., Visanji, N. P., Liu, L. W. C., Lang, A. E., & Pfeiffer, R. F. (2015) · The Lancet Neurology · doi:10.1016/s1474-4422(15)00007-1 · Cited by 1,016
Self-citationDiscovery and inhibition of an interspecies gut bacterial pathway for Levodopa metabolism
Maini Rekdal, V., Bess, E. N., Bisanz, J. E., Turnbaugh, P. J., & Balskus, E. P. (2019) · Science · doi:10.1126/science.aau6323 · Cited by 753
van Kessel, S. P., Frye, A. K., El-Gendy, A. O., Castejon, M., Keshavarzian, A., van Dijk, G., & El Aidy, S. (2019) · Nature Communications · doi:10.1038/s41467-019-08294-y · Cited by 521
The role of small intestinal bacterial overgrowth in Parkinson's disease
Fasano, A., Bove, F., Gabrielli, M., Petracca, M., Zocco, M. A., Ragazzoni, E., Barbaro, F., Piano, C., Fortuna, S., Tortora, A., et al. (2013) · Movement Disorders · doi:10.1002/mds.25522 · Cited by 344 · cited 9×
“DOI: 10.1002/mds.28248 2250 Movement Disorders, Vol. 35, No. 12, 2020 issue worldwide, especially in Asia, Africa, Latin America, and the Caribbean, with approximately 4.4 billion individuals estimated to be HP positive in 2015.2,3 As well as a causative role in peptic ulcers and gastric cancer, chronic systemic infla…”
BackgroundResultInfluentialSmall intestinal bacterial overgrowth in Parkinson's disease
Tan, A. H., Mahadeva, S., Thalha, A. M., Gibson, P. R., Kiew, C. K., Yeat, C. M., Ng, S. W., Ang, S. P., Chow, S. K., Tan, C. T., et al. (2014) · Parkinsonism & Related Disorders · doi:10.1016/j.parkreldis.2014.02.019 · Cited by 274 · cited 8×
“4% found in our previous cross-sectional study.(12) Only 37.”
BackgroundMethodInfluentialHelicobacter pylori eradication and l-dopa absorption in patients with PD and motor fluctuations
Pierantozzi, M., Pietroiusti, A., Brusa, L., Galati, S., Stefani, A., Lunardi, G., Fedele, E., Sancesario, G., Bernardi, G., Bergamaschi, A., et al. (2006) · Neurology · doi:10.1212/01.wnl.0000221672.01272.ba · Cited by 199 · cited 8×
“The lack of improvement of MDS-UPDRS motor scores at 12 weeks (indeed, with a trend favoring placebo) is similar to the findings of an open-label study selecting only motor-fluctuating patients,(7) but contrasts with another open-label study using a similar end point(8) and a previous smaller RCT reporting improvement…”
BackgroundResultInfluentialHelicobacter pylori infection and motor fluctuations in patients with Parkinson's disease
Lee, W. Y., Yoon, W. T., Shin, H. Y., Jeon, S. H., & Rhee, P. (2008) · Movement Disorders · doi:10.1002/mds.22190 · Cited by 110 · cited 1×
“6 points after HP eradication with follow-up periods of 3 weeks,(9) 12 weeks,(8) and 1 year,(14) while one (n = 34) showed improvement in onset (≈20 minutes) and duration (≈24 minutes) of ON time based on 72-hour diaries at 3 months.(7) Due to a lack of larger RCTs using validated outcome measures of motor function, t…”
BackgroundHuang, H.-K., Wang, J.-H., Lei, W.-Y., Chen, C.-L., Chang, C.-Y., & Liou, L.-S. (2018) · Parkinsonism & Related Disorders · doi:10.1016/j.parkreldis.2017.11.331 · Cited by 106 · cited 2×
“As well as a causative role in peptic ulcers and gastric cancer, chronic systemic inflammation induced by HP infection is hypothesized to influence the development and progression of neurological disorders, such as Parkinson’s disease (PD), and two large population-based studies support a link between HP infection and…”
BackgroundResultLiu, H., Su, W., Li, S., Du, W., Ma, X., Jin, Y., Li, K., & Chen, H. (2017) · Clinical Neurology and Neurosurgery · doi:10.1016/j.clineuro.2017.07.003 · Cited by 43 · cited 1×
“Evidence also suggests that treatment effect estimates may be biased and exaggerated when outcome assessors are not blinded, as was the case in previous studies.(8,9,14) It was postulated that short-term improvements in motor outcomes after HP eradication occurred primarily because of improvement in levodopa pharmacok…”
Result
Cited by
The microbiome–gut–brain axis in Parkinson disease — from basic research to the clinic
Tan, A. H., Lim, S. Y., & Lang, A. E. (2022) · Nature Reviews Neurology · doi:10.1038/s41582-022-00681-2 · Cited by 392
Self-citationGut Microbial Ecosystem in Parkinson Disease: New Clinicobiological Insights from Multi‐Omics
Tan, A. H., Chong, C. W., Lim, S., Yap, I. K. S., Teh, C. S. J., Loke, M. F., Song, S., Tan, J. Y., Ang, B. H., Tan, Y. Q., et al. (2021) · Annals of Neurology · doi:10.1002/ana.25982 · Cited by 196
Self-citationMetta, V., Leta, V., Mrudula, K. R., Prashanth, L. K., Goyal, V., Borgohain, R., Chung-Faye, G., & Chaudhuri, K. R. (2022) · Journal of Neurology · doi:10.1007/s00415-021-10567-w · Cited by 130
Potential roles of gut microbiota and microbial metabolites in Parkinson’s disease
Zheng, S.-Y., Li, H.-X., Xu, R.-C., Miao, W.-T., Dai, M.-Y., Ding, S.-T., & Liu, H.-D. (2021) · Ageing Research Reviews · doi:10.1016/j.arr.2021.101347 · Cited by 101
The gut-brain axis and Parkinson disease: Clinical and pathogenetic relevance
Menozzi, E., Macnaughtan, J., & Schapira, A. H. V. (2021) · Annals of Medicine · doi:10.1080/07853890.2021.1890330 · Cited by 81
Metadata
- Authors
- Tan, A. H., Lim, S., Mahadeva, S., Loke, M. F., Tan, J. Y., Ang, B. H., Chin, K. P., Mohammad Adnan, A. F., Ong, S. M. C., Ibrahim, A. I., Zulkifli, N., Lee, J. K., Lim, W. T., Teo, Y. T., Kok, Y. L., Ng, T. Y., Tan, A. G. S., Zulkifle, I. M., Ng, C. K., Ee, S. S., Arafin, S., Mohamad Shukori, K., Vadivelu, J. S., Marras, C., Fox, S. H., & Lang, A. E.
- Venue
- Movement Disorders
- Publisher
- Wiley
- Published
- 2020-09-07
- Volume
- 35
- Issue
- 12
- Pages
- 2250-2260
- ISSN
- 0885-3185 (ISSN-L)
- 1531-8257
- OpenAlex
- W3084082471
- Cited by
- 76
- References
- 9
- FWCI
- 3.99
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Helicobacter pylori Eradication in Parkinson's Disease: A Randomized Placebo‐Controlled Trial. https://app.cochat.ai/papers/10.1002/mds.28248
- The paper
- Tan, A. H., Lim, S., Mahadeva, S., Loke, M. F., Tan, J. Y., Ang, B. H., Chin, K. P., Mohammad Adnan, A. F., Ong, S. M. C., Ibrahim, A. I., Zulkifli, N., Lee, J. K., Lim, W. T., Teo, Y. T., Kok, Y. L., Ng, T. Y., Tan, A. G. S., Zulkifle, I. M., Ng, C. K., . . . Lang, A. E. (2020). Helicobacter pylori Eradication in Parkinson's Disease: A Randomized Placebo‐Controlled Trial. Movement Disorders. https://doi.org/10.1002/mds.28248
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.